TY - JOUR
T1 - Complementary Predictors for Asthma Attack Prediction in Children
T2 - Salivary Microbiome, Serum Inflammatory Mediators, and Past Attack History
AU - Shahbazi Khamas, Shahriyar
AU - Brinkman, Paul
AU - Neerincx, Anne H.
AU - Vijverberg, Susanne J.H.
AU - Hashimoto, Simone
AU - Blankestijn, Jelle M.
AU - Duitman, Jan Willem
AU - Dekker, Tamara
AU - Smids, Barbara S.
AU - Terheggen-Lagro, Suzanne W.J.
AU - Lutter, René
AU - Metwally, Nariman K.A.
AU - Sondaal, Fleur
AU - Haarman, Eric G.
AU - Sterk, Peter J.
AU - Adcock, Ian M.
AU - Auffray, Charles
AU - Bang, Corinna
AU - Bansal, Aruna T.
AU - Buntrock-Döpke, Heike
AU - Bønnelykke, Klaus
AU - Bush, Andrew
AU - Chawes, Bo Lund
AU - Chung, Kian Fan
AU - Corcuera-Elosegui, Paula
AU - Dahlén, Sven Erik
AU - Djukanovic, Ratko
AU - Fleming, Louise J.
AU - Fowler, Stephen J.
AU - Franke, Andre
AU - Frey, Urs
AU - Gorenjak, Mario
AU - Brandstetter, Susanne
AU - Harner, Susanne
AU - Hedlin, Gunilla
AU - Kabesch, Michael
AU - Zounemat-Kermani, Nazanin
AU - Kheirolldein, Parastoo
AU - Kiefer, Alexander
AU - Konradsen, Jon R.
AU - Kraneveld, Aletta D.
AU - López-Fernández, Leyre
AU - Murray, Clare S.
AU - Nordlund, Björn
AU - Pino-Yanes, Maria
AU - Potočnik, Uroš
AU - Roberts, Graham
AU - Stokholm, Jakob
AU - Thorsen, Jonathan
AU - Vissing, Nadja H.
AU - Sardón-Prado, Olaia
AU - Shaw, Dominick E
AU - Singer, Florian
AU - Sousa, Ana R
AU - Toncheva, Antoaneta A
AU - Wolff, Christine
AU - Abdel-Aziz, Mahmoud I
AU - Maitland-van der Zee, Anke H
AU - the SysPharmPediA and U-BIOPRED Consortia
N1 - Publisher Copyright:
© 2025 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2026/2
Y1 - 2026/2
N2 - Background: Early identification of children at risk of asthma attacks is important for optimizing treatment strategies. We aimed to integrate salivary microbiome and serum inflammatory mediator profiles with asthma attacks history to develop a comprehensive predictive model for future attacks. Methods: This study contained a discovery (SysPharmPediA) and a replication phase (U-BIOPRED). School-aged children with asthma were classified into at risk and no-risk groups, based on the presence or absence of one or more severe attacks during one-year follow-up. Prediction models were developed using random forest on the training set (70%) with data on past asthma attacks, microbiome composition, serum inflammatory mediator levels, and their combinations and then tested on the rest of the population (30%). Outcomes were replicated in a subset of children with severe asthma from U-BIOPRED. Results: Complete data were available for 154 children (SysPharmPediA = 121, U-BIOPRED = 33). In discovery, the model based on past attacks resulted in an area under the receiving characteristic curve (AUROCC) ~ 0.7. Models including six salivary bacteria or six inflammatory mediators achieved similar results. The combined model incorporating seven features, past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, TIMP-4, VEGF, and MIP-3β achieved the highest accuracy with AUROCC ~0.87. The combined model in the U-BIOPRED limited to available inflammatory mediators (VEGF), and incorporating past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, resulted in an AUROCC of 0.84. Conclusion: Serum inflammatory mediators and salivary microbiome complement asthma attacks history for predicting future attacks. These results highlight the imperative for continued investigation into oral microbiota and its interaction with the immune system.
AB - Background: Early identification of children at risk of asthma attacks is important for optimizing treatment strategies. We aimed to integrate salivary microbiome and serum inflammatory mediator profiles with asthma attacks history to develop a comprehensive predictive model for future attacks. Methods: This study contained a discovery (SysPharmPediA) and a replication phase (U-BIOPRED). School-aged children with asthma were classified into at risk and no-risk groups, based on the presence or absence of one or more severe attacks during one-year follow-up. Prediction models were developed using random forest on the training set (70%) with data on past asthma attacks, microbiome composition, serum inflammatory mediator levels, and their combinations and then tested on the rest of the population (30%). Outcomes were replicated in a subset of children with severe asthma from U-BIOPRED. Results: Complete data were available for 154 children (SysPharmPediA = 121, U-BIOPRED = 33). In discovery, the model based on past attacks resulted in an area under the receiving characteristic curve (AUROCC) ~ 0.7. Models including six salivary bacteria or six inflammatory mediators achieved similar results. The combined model incorporating seven features, past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, TIMP-4, VEGF, and MIP-3β achieved the highest accuracy with AUROCC ~0.87. The combined model in the U-BIOPRED limited to available inflammatory mediators (VEGF), and incorporating past asthma attacks, Capnocytophaga, Corynebacterium, and Cardiobacterium, resulted in an AUROCC of 0.84. Conclusion: Serum inflammatory mediators and salivary microbiome complement asthma attacks history for predicting future attacks. These results highlight the imperative for continued investigation into oral microbiota and its interaction with the immune system.
KW - 16S rRNA
KW - asthma
KW - biomarker
KW - exacerbations
KW - precision medicine
KW - saliva
KW - Prognosis
KW - Humans
KW - Male
KW - Asthma/diagnosis
KW - Microbiota
KW - Inflammation Mediators/blood
KW - Adolescent
KW - Female
KW - Biomarkers/blood
KW - Saliva/microbiology
KW - Child
UR - https://www.scopus.com/pages/publications/105013758169
U2 - 10.1111/all.70004
DO - 10.1111/all.70004
M3 - Journal article
C2 - 40823900
AN - SCOPUS:105013758169
SN - 0105-4538
VL - 81
SP - 413
EP - 426
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 2
ER -